Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Mary Dohrmann

Cardiovascular Disease Columbia, MO Medical Doctor

NPI 1912959412 CMS profile 222508

500 N Keene St Ste 406, Mc 306, Columbia, MO 65201

Open in the dashboard

General payments

$675

18 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Mary Dohrmann of Columbia, MO is reported in the CMS Open Payments database as having received $675 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 32nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $150 1
2022 General $18 1
2021 General $183 3
2020 General $131 4
2019 General $193 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Dohrmann
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Mary Dohrmann were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Mary Dohrmann Cardiovascular Disease median Middle half National median
2019 $193 $450 $127–$1,392 $163
2020 $131 $242 $77–$751 $114
2021 $183 $335 $101–$1,037 $132
2022 $18 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $150 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Biosense Webster, Inc. $155 1 payment
  2. Biotronik Inc. $150 1 payment
  3. Medtronic Vascular, Inc. $117 3 payments
  4. Pfizer Inc. $72 5 payments
  5. Abbott Laboratories $68 1 payment
  6. Novartis Pharmaceuticals Corporation $34 2 payments
  7. Amgen Inc. $19 1 payment
  8. Siemens Medical Solutions USA, Inc. $18 1 payment
  9. Janssen Pharmaceuticals, Inc $16 1 payment
  10. E.R. Squibb & Sons, L.L.C. $13 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $675 18 payments
Products named General payments · program years 2019–2024
  1. Pentaray Nav $155 1 payment
  2. Orsiro Mission $150 1 payment
  3. Claria MRI $117 3 payments
  4. ELIQUIS $72 5 payments
  5. Durata Defibrillation ICD Lead $68 1 payment
  6. ENTRESTO $34 2 payments
  7. VYNDAQEL $30 2 payments
  8. Repatha $19 1 payment
  9. ACUSON SC2000 Diagnostic Ultrasound System $18 1 payment
  10. XARELTO $16 1 payment
  11. Other $25 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

786

Median for Cardiology: 2,533

Drug cost

$181,395

Median for Cardiology: $485,213

Branded share of claims

24.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 78 $89,731
Xarelto Rivaroxaban Brand 30 $34,587
Repatha Sureclick Evolocumab Brand 29 $26,942
Entresto Sacubitril/Valsartan Brand 12 $21,714
Atorvastatin Calcium Generic 108 $1,304
Metoprolol Succinate Generic 57 $1,055
Amiodarone Hcl Generic 14 $875
Losartan Potassium Generic 50 $690
Warfarin Sodium Generic 49 $577
Metoprolol Tartrate Generic 47 $410

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$35,991

Medicare's payments for the services billed

Medicare patients

1,521

Average age 72

Services billed

2,145

812 women, 709 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Atrial fibrillation 38%
Diabetes 35%
Heart failure 35%
Ischemic heart disease 35%
Chronic kidney disease 32%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record